Internal Medicine, Hematology & Oncology · Washington, DC
NPI
1578670600
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
3
Medicare group memberships
Hospitals
2
Hospital affiliations
2041 Georgia Ave NW Ste 5100
Washington, DC, 20060
Phone (202) 865-6625
Groups this clinician bills Medicare through
Medicare paid, 2024
$25K
278 services
Medicare patients, 2024
100
Average age 70
Drug cost, 2024
$1.9M
703 prescriptions
Company payments, 2025
$5,829
From 25 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ravi P Sarma was code 99232 (hospital e&m - subsequent), 74 times for 34 patients. In total Ravi P Sarma billed 278 services in 13 codes, and Medicare paid $25K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-12-06.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 74 | 34 | $67.45 | $4,991 |
| 99213 Office E&M - Established | Office | 62 | 33 | $71.58 | $4,438 |
| 99214 Office E&M - Established | Office | 50 | 30 | $107.08 | $5,354 |
| 99233 Hospital E&M - Subsequent | Facility | 32 | 16 | $101.18 | $3,238 |
| 99223 Hospital E&M - Initial | Facility | 18 | 18 | $141.75 | $2,552 |
| 99204 Office E&M - New | Office | 11 | 11 | $148.35 | $1,632 |
By year: 2022 $39K for 403 services; 2023 $20K for 213 services; 2024 $25K for 278 services.
Medicare prescription drug claims, 2024
In 2024, the drug Ravi P Sarma prescribed most often to Medicare patients was Anastrozole, with 79 prescriptions and refills. In total Ravi P Sarma wrote 703 Medicare prescriptions that cost $1.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 79 | 187 | 19 | $1,303 |
| Keytruda Pembrolizumab | 44 | 44 | Under 11 | $472K |
| Diphenhydramine Hcl Generic | 38 | 38 | Under 11 | $117 |
| Famotidine Famotidine/Pf | 29 | 29 | Under 11 | $71.22 |
| Granisetron Hcl Generic | 23 | 23 | Under 11 | $229 |
| Ondansetron Hcl Generic | 21 | 21 | 11 | $223 |
| Dexamethasone Sodium Phosphate Generic | 21 | 21 | Under 11 | $58.69 |
| Olanzapine Generic | 21 | 21 | Under 11 | $126 |
| Fulvestrant Generic | 21 | 21 | Under 11 | $4,952 |
| Dexamethasone Generic | 19 | 20 | Under 11 | $190 |
| Granisetron Hcl Granisetron Hcl/Pf | 18 | 18 | Under 11 | $194 |
| Sprycel Dasatinib | 18 | 18 | Under 11 | $332K |
| Eliquis Apixaban | 18 | 18 | Under 11 | $12K |
| Amlodipine Besylate Generic | 17 | 27 | Under 11 | $17.35 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 17 | 17 | Under 11 | $687 |
Brand drugs: 238 claims; generic drugs: 465 claims; opioid claims: 24.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ravi P Sarma $5,829 ($5,829 in general payments such as food, travel and fees) from 25 companies. The largest payer was Incyte Corporation with $3,711.
| Company | Payments | Amount |
|---|---|---|
| Incyte Corporation INCY | 12 | $3,711 |
| Abbvie Inc. ABBV | 7 | $233 |
| AstraZeneca Pharmaceuticals LP AZN | 8 | $203 |
| Novartis Pharmaceuticals Corporation NVS | 8 | $199 |
| Daiichi Sankyo Inc. 4568.T | 7 | $182 |
| E.R. Squibb & Sons, L.L.C. BMY | 7 | $169 |
| Regeneron Healthcare Solutions, Inc. REGN | 6 | $167 |
| Janssen Biotech, Inc. JNJ | 6 | $160 |
| Gilead Sciences, Inc. GILD | 5 | $145 |
| Merck Sharp & Dohme LLC MRK | 4 | $107 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.